Tag: AML
-
Heart Failure in AML: New Evidence on Anthracycline Cardiotoxicity
Overview A comprehensive meta-analysis led by researchers from the Netherlands sheds new light on the risk of heart failure in patients with acute myeloid leukemia (AML) who receive anthracycline-based induction therapy. By systematically reviewing 41 studies including 5,995 AML patients, the study consolidates what clinicians have long suspected: anthracyclines, while effective for achieving remission, carry…
-
Heart Failure in AML: New Evidence Emerges
New Evidence on Cardiotoxicity in AML Treatment A comprehensive new systematic review analyzed 41 studies involving 5,995 patients with acute myeloid leukemia (AML) who received anthracycline-based regimens during remission induction. The pooled rate of heart failure in this population was 3.2%, with notable differences depending on the anthracycline used: 2.3% with daunorubicin, 5.0% with idarubicin,…
-
New Evidence on Heart Failure in AML Treated with Anthracyclines: What Clinicians Need to Know
Overview Heart failure in AML remains a critical concern for patients undergoing induction therapy with anthracycline-based regimens. A comprehensive meta-analysis led by researchers in the Netherlands analyzed 41 studies totaling 5,995 AML patients. The study quantified the burden of heart failure and highlighted substantial variability depending on the specific anthracycline used. These findings reinforce the…